LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals-Reference-Cited by-同舟云学术

LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals

Published:2022-10-06 Issue:8 Volume:134 Page:752-762
ISSN:0032-5481
Container-title:Postgraduate Medicine
language:en
Short-container-title:Postgraduate Medicine

Author:

Underberg James¹^ORCID,Toth Peter P.²^ORCID,Rodriguez Fatima³^ORCID

Affiliation:

1. Department of Medicine, NYU Grossman School of Medicine, New York, NY, USA

2. Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA

3. Division of Cardiovascular Medicine and the Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA

Funder

harmaceuticals Corporation, Eas

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/00325481.2022.2117498

Reference113 articles.

1. Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease

2. Nelson S, Whitsel L, Khavjou O, et al. Projections of cardiovascular disease prevalence and costs: 2015–2035. Technical report. 2016.

3. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

4. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Closing the gap between guidelines and clinical practice for managing dyslipidemia: where are we now?;Expert Review of Cardiovascular Therapy;2024-09

2. Review of Recent Literature and Updates in Nonstatin Cholesterol Management;Mayo Clinic Proceedings;2024-09

3. Safety and Effectiveness of High‐Intensity Statins Versus Low/Moderate‐Intensity Statins Plus Ezetimibe in Patients With Atherosclerotic Cardiovascular Disease for Reaching LDL‐C Goals: A Systematic Review and Meta‐Analysis;Clinical Cardiology;2024-08

4. Effects of Inclisiran in Patients With Atherosclerotic Cardiovascular Disease;Mayo Clinic Proceedings;2024-08

5. Adherence to the 2018 AHA cholesterol management guideline in hyperlipidemia treatment among adults in an outpatient setting;Frontiers in Cardiovascular Medicine;2024-07-10